Coleman Brenda L, Gutmanis Iris, McGovern Ian, Haag Mendel
Sinai Health, Toronto, ON M5G 2A2, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada.
Vaccines (Basel). 2023 Oct 17;11(10):1607. doi: 10.3390/vaccines11101607.
Cell-based seasonal influenza vaccine viruses may more closely match recommended vaccine strains than egg-based options. We sought to evaluate the effectiveness of seasonal cell-based quadrivalent influenza vaccine (QIVc), as reported in the published literature. A systematic literature review was conducted (PROSPERO CRD42020160851) to identify publications reporting on the effectiveness of QIVc in persons aged ≥6 months relative to no vaccination or to standard-dose, egg-based quadrivalent or trivalent influenza vaccines (QIVe/TIVe). Publications from between 1 January 2016 and 25 February 2022 were considered. The review identified 18 relevant publications spanning three influenza seasons from the 2017-2020 period, with an overall pooled relative vaccine effectiveness (rVE) of 8.4% (95% CI, 6.5-10.2%) for QIVc vs. QIVe/TIVe. Among persons aged 4-64 years, the pooled rVE was 16.2% (95% CI, 7.6-24.8%) for 2017-2018, 6.1% (4.9-7.3%) for 2018-2019, and 10.1% (6.3-14.0%) for 2019-2020. For adults aged ≥65 years, the pooled rVE was 9.9% (95% CI, 6.9-12.9%) in the egg-adapted 2017-2018 season, whereas there was no significant difference in 2018-2019. For persons aged 4-64 years, QIVc was consistently more effective than QIVe/TIVe over the three influenza seasons. For persons aged ≥65 years, protection with QIVc was greater than QIVe or TIVe during the 2017-2018 season and comparable in 2018-2019.
与基于鸡蛋的流感疫苗相比，基于细胞的季节性流感疫苗病毒可能与推荐的疫苗毒株更匹配。我们试图评估已发表文献中报道的季节性四价细胞流感疫苗（QIVc）的有效性。进行了一项系统的文献综述（PROSPERO CRD42020160851），以确定关于QIVc在≥6个月龄人群中相对于未接种疫苗或标准剂量、基于鸡蛋的四价或三价流感疫苗（QIVe/TIVe）有效性的报道。考虑了2016年1月1日至2022年2月25日期间的出版物。该综述确定了18篇相关出版物，涵盖2017 - 2020年期间的三个流感季节，QIVc与QIVe/TIVe相比的总体合并相对疫苗效力（rVE）为8.4%（95%CI，6.5 - 10.2%）。在4 - 64岁人群中，2017 - 2018年的合并rVE为16.2%（95%CI，7.6 - 24.8%），2018 - 2019年为6.1%（4.9 - 7.3%），2019 - 2020年为10.1%（6.3 - 14.0%）。对于≥65岁的成年人，在适应鸡蛋的2017 - 2018季节，合并rVE为9.9%（95%CI，6.9 - 12.9%），而在2018 - 2019年没有显著差异。对于4 - 64岁人群，在三个流感季节中，QIVc始终比QIVe/TIVe更有效。对于≥65岁人群，在2017 - 2018季节，QIVc的保护作用大于QIVe或TIVe，在2018 - 2019年相当。
